-
Sector Analysis
Ammonia Industry Capacity and Capital Expenditure Forecasts with Details of Active and Planned Plants to 2028
Ammonia Industry Capacity & CapEx Overview The ammonia industry capacity was 240.38 million tonnes per annum (mtpa) in 2023 and will grow at an AAGR of more than 5% during 2023-2028. Around 113 planned and announced plants are scheduled to start operations by 2028, primarily in North America and FSU to meet the growing demand for nitrogen-based fertilizers in the agriculture industry. Additionally, the elevating cost of feedstock natural gas and the rise of end-users with decarbonization goals are factors...
-
Sector Analysis
Ethylene Glycol Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Ethylene Glycol Industry Capacity & CapEx Overview The Ethylene Glycol industry capacity was 60.06 million tonnes per annum (mtpa) in 2023 and it is expected to increase at an AAGR of more than 5% during 2023-2028. Around 40 planned and announced plants are slated to come online by 2028, primarily in Asia and the Middle East. This will boost the market growth during the forecast years. Ethylene Glycol Industry Capacity and CapEx Outlook, 2023-2028 (mtpa) Buy the Full Report for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Burkitt Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene...
-
Product Insights
Transcription Activator BRG1 – Drugs In Development, 2023
Global Markets Direct’s Transcription Activator BRG1 provides in depth analysis on Transcription Activator BRG1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transcription Activator BRG1 targeted therapeutics...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate 4-1BBL And To Target CD19 For B-Cell Malignancies in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical...
-
Product Insights
Calcium Activated Neutral Protease – Drugs In Development, 2023
Global Markets Direct’s Calcium Activated Neutral Protease provides in depth analysis on Calcium Activated Neutral Protease targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcium Activated Neutral...
-
Product Insights
Plasminogen Activator Inhibitor 1 – Drugs In Development, 2023
Global Markets Direct’s Plasminogen Activator Inhibitor 1 provides in depth analysis on Plasminogen Activator Inhibitor 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen Activator Inhibitor...
-
Product Insights
Proteinase Activated Receptor 2 – Drugs In Development, 2023
Global Markets Direct’s Proteinase Activated Receptor 2 provides in depth analysis on Proteinase Activated Receptor 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proteinase Activated Receptor...